Hannah Green

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
  2. ncbi The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
  3. ncbi Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
    David Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:771-7. 2008
  4. ncbi Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
  5. ncbi Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom
    Deenan Pillay
    Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
    J Infect Dis 192:967-73. 2005
  6. ncbi Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children
    Marthe LePrevost
    Family Clinic, North West London NHS Trust, London, United Kingdom
    Pediatr Infect Dis J 25:533-7. 2006
  7. ncbi HIV drug resistance testing: is the evidence really there?
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 9:641-8. 2004
  8. ncbi Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial
    Graham P Taylor
    Department of GU Medicine and Communicable Diseases, Faculty of Medicine, Imperial College, London, UK
    Retrovirology 3:63. 2006
  9. ncbi Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy
    Marietta Charakida
    Vascular Physiology Unit, Institute of Child Health, London, UK
    Circulation 112:103-9. 2005
  10. ncbi Antiretroviral drug resistance in HIV-infected children: implications for long-term treatment
    Gareth Tudor-Williams
    MRC Clinical Trials Unit, London, UK
    J HIV Ther 12:99-100. 2007

Collaborators

Detail Information

Publications11

  1. ncbi A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
    ..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure...
  2. ncbi The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
    ..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable...
  3. ncbi Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
    David Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:771-7. 2008
    ..These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure...
  4. ncbi Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
    ..The study aim was to determine how resistance testing influences outcome of first-line highly active antiretroviral therapy (HAART) in routine practice in the United Kingdom...
  5. ncbi Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom
    Deenan Pillay
    Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
    J Infect Dis 192:967-73. 2005
    ..Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy...
  6. ncbi Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children
    Marthe LePrevost
    Family Clinic, North West London NHS Trust, London, United Kingdom
    Pediatr Infect Dis J 25:533-7. 2006
    ..CONCLUSION: Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily...
  7. ncbi HIV drug resistance testing: is the evidence really there?
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 9:641-8. 2004
    ..To assess the strength of evidence supporting the routine use of HIV drug resistance testing...
  8. ncbi Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial
    Graham P Taylor
    Department of GU Medicine and Communicable Diseases, Faculty of Medicine, Imperial College, London, UK
    Retrovirology 3:63. 2006
    ..We therefore conducted a randomised, double blind, placebo controlled study of six months combination therapy with these nucleoside analogues in sixteen patients...
  9. ncbi Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy
    Marietta Charakida
    Vascular Physiology Unit, Institute of Child Health, London, UK
    Circulation 112:103-9. 2005
    ..The purpose of this study was to determine the impact of HIV infection and antiretroviral therapy (ART) on markers of early vascular disease in children...
  10. ncbi Antiretroviral drug resistance in HIV-infected children: implications for long-term treatment
    Gareth Tudor-Williams
    MRC Clinical Trials Unit, London, UK
    J HIV Ther 12:99-100. 2007
  11. ncbi Treatment interruption in children with HIV infection
    Hannah Green
    Medical Research Council Clinical Trials Unit, London, UK
    Curr Opin HIV AIDS 2:62-8. 2007
    ..It is vital that this research continues as antiretroviral therapy is rolled out to increasing numbers of young children in resource-limited settings...